Effect of Triamcinolone and Jelfum in reducing the symptoms of allergic rhinitis

Comparative survey of the effectiveness of topical injection of Triamcinolone and Jelfum with Triamcinolone on reducing the symptoms of patients with allergic rhinitis

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210915052490N1

Enrollment

Registered

2021-10-10

Start date

2021-09-04

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis. Other allergic rhinitis

Interventions

Intervention 1: Intervention group: Half a cc of Triamcinolone 40 ml Per mg is injected into the septum. Intervention 2: Intervention group: Jelfum impregnated with triamcinolone is placed Intranasall

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ARIA Criteria Diagnosis of allergic rhinitis

Exclusion criteria

Exclusion criteria: History of rhinoplasty Anatomical disorders of the nose Persistent asthma Prolonged use of corticosteroids Tuberculosis Diabetes Chronic systemic diseases Pregnancy

Design outcomes

Primary

Measure	Time frame
Sneezing. Timepoint: At the beginning of the study (before the intervention) and 7, 14, 21 and 28 days after the intervention. Method of measurement: Based on question from the person (The rate of patient sneezing based on the number of episodes of the patient's daily sneezing).;Runny nose. Timepoint: At the beginning of the study (before the intervention) and 7, 14, 21 and 28 days after the intervention. Method of measurement: Based on a question from the person (number of sheets of tissue paper consumed by the patient per day).;Nasal congestion. Timepoint: At the beginning of the study (before the intervention) and 7, 14, 21 and 28 days after the intervention. Method of measurement: Based on the scores that patient gives to these symptoms from zero to three.;Itchy nose. Timepoint: At the beginning of the study (before the intervention) and 7, 14, 21 and 28 days after the intervention. Method of measurement: Based on the scores that patient gives to these symptoms from zero to three.	—

Measure

Time frame

Sneezing. Timepoint: At the beginning of the study (before the intervention) and 7, 14, 21 and 28 days after the intervention. Method of measurement: Based on question from the person (The rate of patient sneezing based on the number of episodes of the patient's daily sneezing).;Runny nose. Timepoint: At the beginning of the study (before the intervention) and 7, 14, 21 and 28 days after the intervention. Method of measurement: Based on a question from the person (number of sheets of tissue paper consumed by the patient per day).;Nasal congestion. Timepoint: At the beginning of the study (before the intervention) and 7, 14, 21 and 28 days after the intervention. Method of measurement: Based on the scores that patient gives to these symptoms from zero to three.;Itchy nose. Timepoint: At the beginning of the study (before the intervention) and 7, 14, 21 and 28 days after the intervention. Method of measurement: Based on the scores that patient gives to these symptoms from zero to three.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmrollah Dehghani

Kermanshah University of Medical Sciences

amrollah.dehghani@kums.ac.ir+98 83 3427 4618

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026